Glenn McGall, Ph.D.
Senior Vice President of Technology
“We are harnessing the latest advances in engineering, biochemistry and physics to develop cutting-edge technologies capable of solving life’s most complicated problems.”
Dr. McGall is leading chemistry research and process development at Centrillion. In 1991, Dr. McGall joined Stephen Fodor’s team at Affymax to begin development of the first commercial DNA array technology based on photo-lithographic synthesis. When Affymetrix was spun out in 1993 to take the technology to market, he continued as Director of Chemistry & Process Development. In 2005 he became Vice President of Chemistry and Process Technologies R&D. Prior to his time at Affymax, Dr. McGall worked as a staff scientist in the nascent field of DNA-based diagnostics at Syva Co.
Dr. McGall received his B.Sc. degree in chemistry and biochemistry in 1981 and his PhD in organic chemistry in 1986 from the University of Toronto, where he investigated the kinetics and mechanisms of oxyphosphorane hydrolysis reactions. Combining his interests in physical organic and nucleic acid chemistry, Dr. McGall undertook a postdoctoral fellowship at the Massachusetts Institute of Technology, where he helped to unravel the mechanisms of DNA degradation by the antitumor drug bleomycin using stable and radioactive isotopes. Dr. McGall has co-authored 45 scientific publications and is the inventor on more than 90 issued US patents.